Beam <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports third quarter cash position of $1.1 billion
Beam Therapeutics reported a net loss of $112.7 million, or $1.10 per share, for the third quarter of 2025, compared to a net loss of $96.7 million, or $1.17 per share, for the same period in 2024. Research and development expenses reached $109.8 million, up from $94.3 million in the third quarter of 2024. General and administrative expenses were $26.7 million, slightly higher than $26.5 million a year earlier. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $1.1 billion, up from $850.7 million on December 31, 2024. The company expects its cash reserves to fund operations into 2028. During the period, Beam continued dose exploration in the BEAM-302 Phase 1/2 study in alpha-1 antitrypsin deficiency, is advancing the BEAM-301 trial in glycogen storage disease Ia, and plans to present updated BEACON Phase 1/2 trial data for BEAM-101 in sickle cell disease at the upcoming American Society of Hematology Annual Meeting. The first subject was also dosed in a healthy volunteer trial of BEAM-103, an anti-CD117 monoclonal antibody.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567777-en) on November 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.